Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

A Phase I/II Trial Evaluating the Use of a Histone Deacetylase Inhibitor Panobinostat (LBH589) in Addition to Glucocorticoids in Patients with Acute Graft-Versus-Host Disease

Lia Perez, MD, Teresa Field, MD PhD, Marcie L Riches, MD MS, Hugo F Fernandez, MD, Frederick L Locke, MD, Brian C Betts, MD, Joseph Pidala, MD PhD, Erika Elmer, CCRP, Francisca Beato, BS, Maritza Lienlaf, MS, Pedro Horna, MD, Alejandro Villagra, PhD, Claudio Anasetti, MD

Blood (2014) 124 (21): 1167.

https://doi.org/10.1182/blood.V124.21.1167.1167

Published: 2014

Journal Articles

Histone Deacetylase Inhibitors Enhance Cell Death In Burkitt Lymphoma Cells By Modulating Expression Of The WNT/β-Catenin Pathway and Survivin

Faye Pais, MBBS, Matthew J. Barth, MD, Rodney R. Miles, MD, PhD, Michelle L. Hermiston, MD, PhD

Blood (2013) 122 (21): 1291.

https://doi.org/10.1182/blood.V122.21.1291.1291

Published: 2013

Journal Articles

CITED2 Facilitates Apoptosis Induced By Histone Deacetylase Inhibitor SAHA In Human Pediatric Pre-B Acute Lymphoblastic Leukemia Cells

Jinwei Du, PhD, Shigemi Matsuyama, PhD, Yu-Chung Yang, PhD

Blood (2013) 122 (21): 2913.

https://doi.org/10.1182/blood.V122.21.2913.2913

Published: 2013

Journal Articles

A Phase I/II Trial Evaluating The Use Of a Histone Deacetylase Inhibitor Panobinostat (LBH589) In Addition To Glucocorticoids In Patients With Acute Graft-Versus-Host Disease

Lia Perez, MD, Hugo F Fernandez, MD, Marcie Tomblyn, MD, MS, Frederick L Locke, MD, Teresa Field, MD, PhD, Joseph Pidala, MD, MS, Erika Elmer, CCRP, Francisca Beato, BS, Alejandro Villagra, PhD, Claudio Anasetti, MD

Blood (2013) 122 (21): 3308.

https://doi.org/10.1182/blood.V122.21.3308.3308

Published: 2013

Journal Articles

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Robert W. Chen, MD, Leslie Popplewell, MD, Paul Frankel, PhD, Tanya Siddiqi, MD, Joel Conrad, BS, Michelle Mott, RN, Myo Htut, MD, Auayporn Nademanee, MD, Stephen J Forman, MD, Mark Kirschbaum, MD

Blood (2012) 120 (21): 3698.

https://doi.org/10.1182/blood.V120.21.3698.3698

Published: 2012

Journal Articles

Direct and Continuous Inhibition of ADAM17 Using a Novel Selective Inhibitor Restores Functional Platelet Yield From Human Pluripotent Stem Cells

Shinji Hirata, Ryoko Jono-Ohnishi, Satoshi Nishimura, M.D., Ph.D, Naoya Takayama, M.D., Ph.D., Sou Nakamura, Hiromitsu Nakauchi, MD, PhD, Takahiko Murata, Ph.D., Koji Eto, M.D., Ph.D.

Blood (2011) 118 (21): 2323.

https://doi.org/10.1182/blood.V118.21.2323.2323

Published: 2011

Journal Articles

Effects of Hepatic Function on the Pharmacokinetics and Safety of Panobinostat in Patients with Advanced Cancer: A Phase I Study

Dagmar Hess, MD, Nicole Hagner, MD, Sally Clive, MD, Hans Gelderblom, MD, PhD, Eva Rossmann, MD, PhD, Neeraj Agarwal, MD, Maria Grazia Porro, PhD, Thomas Hengelage, PhD, Annie St-Pierre, PhD, Lucien Gazi, PhD, Jason Li, PhD, Margaret M. Woo, PharmD, Sunil Sharma, MD

Blood (2011) 118 (21): 5007.

https://doi.org/10.1182/blood.V118.21.5007.5007

Published: 2011

Journal Articles

A Phase II Trial of Panobinostat, an Orally Available Deacetylase Inhibitor (DACi), in Patients with Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET), and Post Polycythemia Vera (PV) Myelofibrosis

Daniel J DeAngelo, MD, PhD, Ayalew Tefferi, MD, Warren Fiskus, PhD, Ruben A. Mesa, MD, Carole S. Paley, MD, Martha Wadleigh, MD, David S. Snyder, MD, Kebede Begna, MD, Michael S. Ondovik, Jessica Rine, Kapil N. Bhalla, MD

Blood (2010) 116 (21): 630.

https://doi.org/10.1182/blood.V116.21.630.630

Published: 2010

Journal Articles

Translating Epigenetic Alterations Into Improvements In Patient Care

Pavan Reddy, MD

Blood (2010) 116 (21): SCI-24.

https://doi.org/10.1182/blood.V116.21.SCI-24.SCI-24

Published: 2010

Journal Articles

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Mark Kirschbaum, MD, Leslie Popplewell, M.D., Maria L Delioukina, MD, Robert w Chen, Vinod Pullarkat, Paul Frankel, Joel Conrad, Joyce Hartshorn, Auayporn Nademanee, M.D., Stephen Forman, MD

Blood (2010) 116 (21): 3957.

https://doi.org/10.1182/blood.V116.21.3957.3957

Published: 2010

Journal Articles

Histone Deacetylase Inhibitors: Potent Inducers of Tumor Latent EBV Thymidine Kinase Induction

Douglas V Faller, Sajal K Ghosh, Susan P Perrine, MD, Robert M Williams, Ronald J Berenson, MD

Blood (2010) 116 (21): 1831.

https://doi.org/10.1182/blood.V116.21.1831.1831

Published: 2010

Journal Articles

Novel Histone Deacetilase (HDAC) Inhibitors: In Vitro Effects on Leukemic Cells

Maria Rosaria Ricciardi, PhD, Roberto Licchetta, Paola Bergamo, Stefano Iacovelli, Andrea Miele, Maria Teresa Petrucci, MD, Michele Milella, MD, Claudio Pisano, PhD, Agostino Tafuri, MD

Blood (2010) 116 (21): 4946.

https://doi.org/10.1182/blood.V116.21.4946.4946

Published: 2010

Journal Articles

The HDAC Inhibitors Trichostatin A (TSA) and Suberoylanilide Hydroxamic Acid (SAHA) Exhibit Multiple Modalities of Benefit for the Vascular Pathology of Sickle Disease.

Robert P Hebbel, MD, Gregory M. Vercellotti, MD, Betty Pace, MD, Anna Solovey, M.D., Rahn Kollander, Chine Abanonu, Julia Nguyen, BS, Julie V. Vineyard, BS, John D Belcher, Ph.D., Fuad Abdulla, Shade Osifuye, John W. Eaton, PhD, Robert Kelm, MD, Arne Slungaard, MD

Blood (2009) 114 (22): 2586.

https://doi.org/10.1182/blood.V114.22.2586.2586

Published: 2009

Journal Articles

Selective HDAC6 Inhibition and Antileukemic Activity of the Novel HDAC Inhibitor ST80 in Myeloid Leukemia Cell Lines.

Bjorn W. Hackanson, MD, Leander Rimmele, Manfred Jung, PhD, Michael Lübbert, MD, PhD

Blood (2009) 114 (22): 4808.

https://doi.org/10.1182/blood.V114.22.4808.4808

Published: 2009

Journal Articles

Dysregulation of Metabolic Genes May Be Normalized by Epigenetic Drugs (Vorinostat, Decitabine) and Nutritional Compounds (Genistein, Vitamin D) in Leukemic Cells.

Heidrun Karlic, PhD, Franz Varga, PhD, Elisabeth Pittermann, MD, Michael Pfeilstocker, MD

Blood (2009) 114 (22): 4423.

https://doi.org/10.1182/blood.V114.22.4423.4423

Published: 2009

Journal Articles

Phenotypic and Functional Effects of Novel HDAC Inhibitor LBH589 On Human Lymphocyte Populations.

Weihua Song, MD, Yu-Tzu Tai, PhD, Teru Hideshima, MD, PhD, Kenneth C. Anderson, Nikhil C. Munshi

Blood (2009) 114 (22): 3681.

https://doi.org/10.1182/blood.V114.22.3681.3681

Published: 2009

Journal Articles

Population Pharmacokinetics of Panobinostat (LBH589) in Patients with Advanced Solid Tumors and Hematologic Malignancies Following Intravenous and Oral Administration.

Marina Savelieva, Praz, Dr., sc., math., Margaret M. Woo, Harald A. Weber, MD, Samit Hirawat, MD, Sofia Paul, PhD, Joanne Schindler, Roland Fisch, PhD

Blood (2009) 114 (22): 3780.

https://doi.org/10.1182/blood.V114.22.3780.3780

Published: 2009

Journal Articles

QT Interval Measurements in Patients with Hematologic Malignancies and Solid Tumors Treated with Oral Panobinostat (LBH589).

Harald A. Weber, MD, Feng Tai, PhD, Sofia Paul, PhD, Joanne Schindler, Margaret M. Woo, Stan Spence, PhD, Jennifer Marlowe, Rong Lin, MD

Blood (2009) 114 (22): 3781.

https://doi.org/10.1182/blood.V114.22.3781.3781

Published: 2009

Journal Articles

LBH589 (panobinostat): A Potential Novel Anti-Switching Therapy.

Abdullah Kutlar, MD, Niren Patel, MBBS, Celalettin Ustun, MD, Kavita Natarajan, MBBS, Anand Jillella, MD, Betsy Clair, Ferdane Kutlar, Rosemary Chandler, BSN, RN, OCN, Steffen E. Meiler, MD, Kapil N. Bhalla, MD

Blood (2009) 114 (22): 2568.

https://doi.org/10.1182/blood.V114.22.2568.2568

Published: 2009

Journal Articles

Deacetylase Inhibitor Cocktails Provide Striking Synergistic Interactions in Human Leukemia Cells.

Michele Cea, MD, Antonia Cagnetta, Floriana Fruscione, Santina Bruzzone, Ph.D., Gabriele Zoppoli, MD, Anna Garuti, Eva Moran, Ph.D., Valentina Grillo, Fabio Ferrando, Salvatore Casciaro, Ivana Pierri, Marco Gobbi, MD, Alberto Ballestrero, MD, Ph.D., Franco Patrone, MD, Ph.D., Alessio Nencioni, MD, Ph.D.

Blood (2009) 114 (22): 4404.

https://doi.org/10.1182/blood.V114.22.4404.4404

Published: 2009

NARROW

A Phase I/II Trial Evaluating the Use of a Histone Deacetylase Inhibitor Panobinostat (LBH589) in Addition to Glucocorticoids in Patients with Acute Graft-Versus-Host Disease

Histone Deacetylase Inhibitors Enhance Cell Death In Burkitt Lymphoma Cells By Modulating Expression Of The WNT/β-Catenin Pathway and Survivin

CITED2 Facilitates Apoptosis Induced By Histone Deacetylase Inhibitor SAHA In Human Pediatric Pre-B Acute Lymphoblastic Leukemia Cells

A Phase I/II Trial Evaluating The Use Of a Histone Deacetylase Inhibitor Panobinostat (LBH589) In Addition To Glucocorticoids In Patients With Acute Graft-Versus-Host Disease

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Direct and Continuous Inhibition of ADAM17 Using a Novel Selective Inhibitor Restores Functional Platelet Yield From Human Pluripotent Stem Cells

Effects of Hepatic Function on the Pharmacokinetics and Safety of Panobinostat in Patients with Advanced Cancer: A Phase I Study

A Phase II Trial of Panobinostat, an Orally Available Deacetylase Inhibitor (DACi), in Patients with Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET), and Post Polycythemia Vera (PV) Myelofibrosis

Translating Epigenetic Alterations Into Improvements In Patient Care

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Histone Deacetylase Inhibitors: Potent Inducers of Tumor Latent EBV Thymidine Kinase Induction

Novel Histone Deacetilase (HDAC) Inhibitors: In Vitro Effects on Leukemic Cells

The HDAC Inhibitors Trichostatin A (TSA) and Suberoylanilide Hydroxamic Acid (SAHA) Exhibit Multiple Modalities of Benefit for the Vascular Pathology of Sickle Disease.

Selective HDAC6 Inhibition and Antileukemic Activity of the Novel HDAC Inhibitor ST80 in Myeloid Leukemia Cell Lines.

Dysregulation of Metabolic Genes May Be Normalized by Epigenetic Drugs (Vorinostat, Decitabine) and Nutritional Compounds (Genistein, Vitamin D) in Leukemic Cells.

Phenotypic and Functional Effects of Novel HDAC Inhibitor LBH589 On Human Lymphocyte Populations.

Population Pharmacokinetics of Panobinostat (LBH589) in Patients with Advanced Solid Tumors and Hematologic Malignancies Following Intravenous and Oral Administration.

QT Interval Measurements in Patients with Hematologic Malignancies and Solid Tumors Treated with Oral Panobinostat (LBH589).

LBH589 (panobinostat): A Potential Novel Anti-Switching Therapy.

Deacetylase Inhibitor Cocktails Provide Striking Synergistic Interactions in Human Leukemia Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only